Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Randomized, Open-labeled, Positive-controlled, Phase II Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.

Next Previous
X
Search
Trial Profile

Multi-center, Randomized, Open-labeled, Positive-controlled, Phase II Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telpegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Xiamen Amoytop Biotech

    • Most Recent Events

    • 15 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 11 Jan 2018 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
    • 28 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top